jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
oftan chlora augnsmyrsli 10 mg/g
santen oy* - chloramphenicolum inn - augnsmyrsli - 10 mg/g
cleye augndropar, lausn 0,12 mg/ml
elara pharmaservices europe limited - naphazoline hydrochloride - augndropar, lausn - 0,12 mg/ml
cosopt sine augndropar, lausn 20 mg/ml+5 mg/ml
santen oy* - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml+5 mg/ml
taflotan sine (taflotan) augndropar, lausn 15 míkróg/ml
santen oy* - tafluprostum inn - augndropar, lausn - 15 míkróg/ml